Safety and Efficacy of Novel Oral Anticoagulants as Compared to Warfarin in Treatment of Atrial Fibrillation

Shubham Mittal; Jasmine Arora; Kartik J. Sharma; Ravneet Kaur; Jasreen Kaur Sandhu

doi:10.36948/ijfmr.2023.v05i04.5418

Safety and Efficacy of Novel Oral Anticoagulants as Compared to Warfarin in Treatment of Atrial Fibrillation

Author(s)	Shubham Mittal, Jasmine Arora, Kartik J. Sharma, Ravneet Kaur, Jasreen Kaur Sandhu
Country	India
Abstract	BACKGROUND - Novel oral anticoagulants (NOACs) are a class of medications used to prevent blood clots thereby various studies have demonstrated their potential benefit in their use in atrial fibrillation. They act by inhibiting clotting factors such as factor Xa or Thrombin. Unlike traditional anticoagulants like Vitamin K antagonist (Warfarin), NOACs have a more predictable effect and require less frequent monitoring. OBJECTIVE – We aim to explore the safety and efficacy of Novel oral anticoagulants as compared to warfarin in the treatment of atrial fibrillation. Additionally, a comparative analysis among NOACs was conducted to determine the most superior among them. METHODS – We performed a pairwise systematic review in patients with atrial fibrillation undergoing anticoagulation with the help of NOAC as compared to those undergoing anticoagulation on Warfarin by analyzing various electronic databases from 2005 till 2023 and filtered 11 studies having 70,801 sample size distributed comparably among the two groups based on our inclusion criteria. RESULTS – There was a slight difference between the safety and efficacy of the NOAC and Warfarin groups. Among the participants, 3019 individuals (8.93%) who were administered Warfarin experienced major bleeding complications, in contrast to 2690 participants (7.26%) who were on NOACs. Regarding the occurrence of stroke, the Warfarin group observed a rate of 987 cases (2.92%), while the NOAC group had 1119 instances (3.02%) of stroke. CONCLUSION – The results of recent NOACs studies emphasizes on the superiority of them as compared to warfarin in both rapid onset of action as well as better patient compliance. Our review suggests a lower risk of bleeding but a slightly higher risk of stroke occurrence in NOACs as compared to the Warfarin group, thereby showing their superiority in clinical utility, though more robust clinical trials are required to establish long-term benefits.
Keywords	Novel oral anticoagulants, atrial fibrillation, Warfarin, Stroke, Bleed
Field	Medical / Pharmacy
Published In	Volume 5, Issue 4, July-August 2023
Published On	2023-08-18
Cite This	Safety and Efficacy of Novel Oral Anticoagulants as Compared to Warfarin in Treatment of Atrial Fibrillation - Shubham Mittal, Jasmine Arora, Kartik J. Sharma, Ravneet Kaur, Jasreen Kaur Sandhu - IJFMR Volume 5, Issue 4, July-August 2023. DOI 10.36948/ijfmr.2023.v05i04.5418
DOI	https://doi.org/10.36948/ijfmr.2023.v05i04.5418
Short DOI	https://doi.org/gsmnns

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 3 Cover Page Vol 6 Isu 2 Cover Page Vol 6 Isu 1

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Safety and Efficacy of Novel Oral Anticoagulants as Compared to Warfarin in Treatment of Atrial Fibrillation

Share this